LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.

    Frikke-Schmidt, Henriette / Hultman, Karin / Galaske, Joseph W / Jørgensen, Sebastian B / Myers, Martin G / Seeley, Randy J

    Molecular metabolism

    2019  Volume 21, Page(s) 13–21

    Abstract: Objective: Analogues of GDF15 (Growth Differentiation Factor 15) are promising new anti-obesity therapies as pharmacological treatment with GDF15 results in dramatic reductions of food intake and body weight. GDF15 exerts its central anorexic effects by ...

    Abstract Objective: Analogues of GDF15 (Growth Differentiation Factor 15) are promising new anti-obesity therapies as pharmacological treatment with GDF15 results in dramatic reductions of food intake and body weight. GDF15 exerts its central anorexic effects by binding to the GFRAL receptor exclusively expressed in the Area Postrema (AP) and the Nucleus of the Solitary Tract (NTS) of the hindbrain. We sought to determine if GDF15 is an indispensable factor for other interventions that cause weight loss and which are also known to act via these hindbrain regions.
    Methods: To explore the role of GDF15 on food choice we performed macronutrient intake studies in mice treated pharmacologically with GDF15 and in mice having either GDF15 or GFRAL deleted. Next we performed vertical sleeve gastrectomy (VSG) surgeries in a cohort of diet-induced obese Gdf15-null and control mice. To explore the anatomical co-localization of neurons in the hindbrain responding to GLP-1 and/or GDF15 we used GLP-1R reporter mice treated with GDF15, as well as naïve mouse brain and human brain stained by ISH and IHC, respectively, for GLP-1R and GFRAL. Lastly we performed a series of food intake experiments where we treated mice with targeted genetic disruption of either Gdf15 or Gfral with liraglutide; Glp1r-null mice with GDF15; or combined liraglutide and GDF15 treatment in wild-type mice.
    Results: We found that GDF15 treatment significantly lowered the preference for fat intake in mice, whereas no changes in fat intake were observed after genetic deletion of Gdf15 or Gfral. In addition, deletion of Gdf15 did not alter the food intake or bodyweight after sleeve gastrectomy. Lack of GDF15 or GFRAL signaling did not alter the ability of the GLP-1R agonist liraglutide to reduce food intake. Similarly lack of GLP-1R signaling did not reduce GDF15's anorexic effect. Interestingly, there was a significant synergistic effect on weight loss when treating wild-type mice with both GDF15 and liraglutide.
    Conclusion: These data suggest that while GDF15 does not play a role in the potent effects of VSG in mice there seems to be a potential therapeutic benefit of activating GFRAL and GLP-1R systems simultaneously.
    MeSH term(s) Animals ; Area Postrema/metabolism ; Bariatric Surgery ; Body Weight/drug effects ; Diet, High-Fat/adverse effects ; Drug Synergism ; Eating/drug effects ; Gastrectomy ; Gene Deletion ; Glial Cell Line-Derived Neurotrophic Factor Receptors/genetics ; Glial Cell Line-Derived Neurotrophic Factor Receptors/metabolism ; Glucagon-Like Peptide-1 Receptor/metabolism ; Growth Differentiation Factor 15/genetics ; Growth Differentiation Factor 15/metabolism ; Growth Differentiation Factor 15/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use ; Liraglutide/therapeutic use ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Obesity/drug therapy ; Obesity/etiology ; Solitary Nucleus/metabolism ; Weight Loss/drug effects
    Chemical Substances GFRAL protein, mouse ; GLP1R protein, human ; Gdf15 protein, mouse ; Glial Cell Line-Derived Neurotrophic Factor Receptors ; Glp1r protein, mouse ; Glucagon-Like Peptide-1 Receptor ; Growth Differentiation Factor 15 ; Hypoglycemic Agents ; Liraglutide (839I73S42A)
    Language English
    Publishing date 2019-01-14
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2212-8778
    ISSN (online) 2212-8778
    DOI 10.1016/j.molmet.2019.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: MnTE-2-PyP modulates thiol oxidation in a hydrogen peroxide-mediated manner in a human prostate cancer cell.

    Tong, Qiang / Zhu, Yuxiang / Galaske, Joseph W / Kosmacek, Elizabeth A / Chatterjee, Arpita / Dickinson, Bryan C / Oberley-Deegan, Rebecca E

    Free radical biology & medicine

    2016  Volume 101, Page(s) 32–43

    Abstract: To improve the treatment of advanced prostate cancer, the development of effective and innovative antitumor agents is needed. Our previous work demonstrated that the ROS (reactive oxygen species) scavenger, MnTE-2-PyP, inhibited human prostate cancer ... ...

    Abstract To improve the treatment of advanced prostate cancer, the development of effective and innovative antitumor agents is needed. Our previous work demonstrated that the ROS (reactive oxygen species) scavenger, MnTE-2-PyP, inhibited human prostate cancer growth and also inhibited prostate cancer migration and invasion. We showed that MnTE-2-PyP treatment altered the affinity of the histone acetyltransferase enzyme, p300, to bind to DNA. We speculate that this may be one mechanism by which MnTE-2-PyP inhibits prostate cancer progression. Specifically, MnTE-2-PyP decreased p300/HIF-1/CREB complex (p300/hypoxia-inducible factor-1/cAMP response element-binding protein) binding to a specific hypoxia-response element (HRE) motif within the plasminogen activator inhibitor-1 (PAI-1) gene promoter region, and consequently, repressed PAI-1 expression. However, it remains unclear how MnTE-2-PyP reduces p300 complex binding affinity to the promoter region of specific genes. In this study, we found that overexpression of Cu/ZnSOD (superoxide dismutase 1, SOD1) significantly suppressed PAI-1 gene expression and p300 complex binding to the promoter region of PAI-1 gene, just as was observed in cells treated with MnTE-2-PyP. Furthermore, catalase (CAT) overexpression rescued the inhibition of PAI-1 expression and p300 binding by MnTE-2-PyP. Taken together, the above findings suggest that hydrogen peroxide (H
    MeSH term(s) Antineoplastic Agents/pharmacology ; Catalase/genetics ; Catalase/metabolism ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cyclic AMP Response Element-Binding Protein/genetics ; Cyclic AMP Response Element-Binding Protein/metabolism ; Epithelial Cells/drug effects ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Humans ; Hydrogen Peroxide/agonists ; Hydrogen Peroxide/metabolism ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Male ; Metalloporphyrins/pharmacology ; Oxidation-Reduction ; Plasminogen Activator Inhibitor 1/genetics ; Plasminogen Activator Inhibitor 1/metabolism ; Promoter Regions, Genetic ; Prostate/drug effects ; Prostate/metabolism ; Prostate/pathology ; Protein Binding ; Superoxide Dismutase-1/genetics ; Superoxide Dismutase-1/metabolism ; p300-CBP Transcription Factors/genetics ; p300-CBP Transcription Factors/metabolism
    Chemical Substances Antineoplastic Agents ; CREB1 protein, human ; Cyclic AMP Response Element-Binding Protein ; HIF1A protein, human ; Hypoxia-Inducible Factor 1, alpha Subunit ; Metalloporphyrins ; Plasminogen Activator Inhibitor 1 ; SERPINE1 protein, human ; SOD1 protein, human ; manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin ; Hydrogen Peroxide (BBX060AN9V) ; Catalase (EC 1.11.1.6) ; Superoxide Dismutase-1 (EC 1.15.1.1) ; p300-CBP Transcription Factors (EC 2.3.1.48) ; p300-CBP-associated factor (EC 2.3.1.48)
    Language English
    Publishing date 2016-09-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 807032-5
    ISSN 1873-4596 ; 0891-5849
    ISSN (online) 1873-4596
    ISSN 0891-5849
    DOI 10.1016/j.freeradbiomed.2016.09.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top